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Abstract: In this paper we propose a flexible cure rate model with frailty term in latent risk,
which is obtained by incorporating a frailty term in risk function of latent competing causes. The
number of competing causes of the event of interest follows negative binomial distribution and
the frailty variable follows power variance function distribution, in which includes other frailty
models such as gamma, positive stable and inverse Gaussian frailty models as special cases. The
proposed model takes into account the presence of covariates and right-censored survival data
suitable for populations with a cure rate. Besides, it allows to quantify the degree of unobserved
heterogeneity induced by unobservable risk factors, in which is important to explain the survival
time. Once the posterior distribution has not close form, Markov chain Monte Carlo simulations
are consider for estimation procedure. We performed several simulation studies and the practical
relevance of the proposed model is demonstrated in a real data set.
Keywords: Bayesian model; Competing causes; Cure rate models; Frailty models; Power vari-
ance function.
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1 Introduction
In survival data, an usual interest is to model the time until the occurrence of a defined
event. In the traditional approach, it is assumed that all units under study are susceptible to
the event of interest that will occur. However, such assumption can be violated because many
studies have what we call “immune” or “cured” elements. The idea is that the event will never
occur for immune units because they are not susceptible to the event of interest. Thus, a class
of models referred as the cure rate models considers that situation and it has been studied by
several authors. The Berkson-Gage model Berkson & Gage (1952) was probably the first model
to propose the cured fraction. This model is based on the assumption that only one cause is
responsible for the occurrence of an event of interest Cooner et al. (2007).
In biomedical studies, an event of interest can be the patient’s death as well as cancer
recurrence, which can be attributed to different latent competing causes as the presence of
an unknown number of cancer cells. These causes are based on the fact that each surviving
carcinogenic cell can be characterized by an unknown time (promotion time) during which the
cell could become a definitive tumor Cobre et al. (2013). The literature on this subject is
extensive. The books of Maller & Zhou (1996); Ibrahim et al. (2001), as well as the articles
Yakovlev & Tsodikov (1996); Chen et al. (1999); Tsodikov et al. (2003); Yin & Ibrahim (2005);
Cooner et al. (2007); Rodrigues et al. (2009, 2011, 2012, 2015); de Castro et al. (2009); Cancho
et al. (2011, 2012, 2013a,b); Borges et al. (2012) could be mentioned as key references.
In the competing causes scenarios, the promotion times are usually assumed to be indepen-
dent and identically distributed, i.e., the carcinogenic cells lifetimes follow a common distribution
function and the most common choices have been exponential, piecewise exponential, Weibull,
among other. Besides, the cure rate models implicitly assume a homogeneous population for the
susceptible units. However, covariates can be included in the model in order to explain some
heterogeneity. But there is an unobserved heterogeneity induced by unobservable risk factors,
which are not considered in the model.
The models that take into account the unobservable heterogeneity are known as frailty models
Vaupel et al. (1979). These models are characterized by the inclusion of a random effect, that
is, an unobservable random variable that represents the information that can not be observed,
such as unobservable risk factors. If an important covariate was not included in the model, this
will increase the unobservable heterogeneity, affecting the inferences about the parameters in
the model. This way, the inclusion of a frailty term can help to relieve this problem.
The frailty term can be included in an additive form in the model. However, a multiplicative
effect on the baseline hazard function is often used. Multiplicative frailty models represent a
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generalization of the proportional hazards model introduced by Cox (1972), which the frailty
term acts multiplicatively on the baseline hazard function. This approach has been studied by
several authors, notably Clayton (1978); Vaupel et al. (1979); Andersen et al. (1993); Hougaard
(1995); Sinha & Dey (1997); Oakes (1982); Balakrishnan & Peng (2006). Other authors, as
Aalen (1988); Hougaard et al. (1994); Price & Manatunga (2001); Peng et al. (2007); Yu & Peng
(2008); Calsavara et al. (2013) considered cure rate models with a frailty term.
This manuscript proposes a new Bayesian cure rate model with a frailty term in risk function
of latent competing causes, called power variance function frailty cure rate model (PVFCR). The
proposed model is obtained of Cancho et al. (2011) models by adding a random effect (frailty
term) on the baseline hazard function that acts multiplicatively in promotion time of each latent
competitive cause. This approach allows that the competitive causes have different frailties, and
that the most frail will fail earlier than the less frail. The distribution of the random effect
is full based on family of power variance function (PVF) distributions suggested by Tweedie
(1984) and derived independently by Hougaard (1986). Besides, we consider that the number
of competing causes related to the occurrence of an event of interest is modeled by the negative
binomial distribution. Another advantage of the proposed model is that the negative binomial
and PVF are flexible distributions and they include as particular cases well-known distributions,
which can be tested for the best fitting in a straightforward way.
Our paper is organized as follows. In Section 2 we formulate the proposed model and Bayesian
inference is described in Section 3. In Section 4 we consider a simulation study under different
scenarios, where we numerically evaluate the performance of the Bayesian estimators as well
as the performance of the proposed model in terms of Conditional Predictive Ordinate (CPO)
criterion when it is compared to usual cure rate model Cancho et al. (2011). An application to
a real data set is presented in Section 5. Finally, some final remarks are considered in Section 6.
2 Frailty cure rate model
The time for the jth competing cause to produce the event of interest (promotion time) is
denoted by Zj , j = 1, . . . , N , where N represents the number of competing causes. The variable
N is unobservable with probability mass function (p.m.f) pn = P (N = n|Θ) for n = 0, 1, . . .. We
assume that, conditional on N and on the parameters vector ϕ, Zj ’s are i.i.d. with cumulative
distribution function F (t|ϕ) and survival function S(t|ϕ) = 1 − F (t|ϕ). Also, we assume that
Z1, Z2, . . . are independent from N .
The observable time of the occurrence of the event of interest is defined as T = min{Z0, Z1, . . .,
ZN}, where P (Z0 =∞) = 1, which leads to a cure rate p0 of the population not susceptible to
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the event occurrence.
Under this setup, according to Rodrigues et al. (2009) the cure rate survival function of the
random variable T , conditional to vector parameters ϑ, is given by
Spop(t|ϑ) = P (T ≥ t|ϑ) =
∞∑
n=0
P (N = n|Θ)[S(t|ϕ)]n = AN [S(t|ϕ)], (1)
where AN [·] is the probability generating function (p.g.f) of the random variable N , which
converges when s = S(t|ϕ) ∈ [0, 1].
From now on we suppose that the number of competing causes, N , conditional to Θ = (η, θ)>,
follows a negative binomial distribution Saha & Paul (2005) with p.m.f
pn = P (N = n|Θ) = Γ(n+ η
−1)
n!Γ(η−1)
(
ηθ
1 + ηθ
)n
(1 + ηθ)−1/η,
n = 0, 1, . . . , θ > 0, η ≥ 0 and 1 + ηθ > 0, so that E(N |Θ) = θ and Var(N |Θ) = θ + ηθ2.
The p.g.f. is given by
AN (s) =
∞∑
n=0
pns
n = {1 + ηθ(1− s)}−1/η , 0 ≤ s ≤ 1. (2)
As discussed by Tournoud & Ecochard (2008), the parameters of the negative binomial distribu-
tion have biological interpretations, which the mean number of competing causes is represented
by θ, whereas η is the dispersion parameter.
So, taking into account (2) in (1), the population survival and density functions are given,
respectively, by
Spop(t|ϑ) = {1 + ηθ[1− S(t|ϕ)]}−1/η, (3)
and
fpop(t|ϑ) = − d
dt
Spop(t|ϕ) = θf(t|ϕ)
{
1 + ηθ
[
1− S(t|ϕ)]}−1/η−1,
where f(t|ϕ) = −dF (t|ϕ)/dt. The cure rate is determined by p0 = limt→∞ Spop(t|ϑ) = (1 +
ηθ)−1/η > 0.
Usually, the most common choices for promotion time distribution that specify the function
S(t|ϕ) have been exponential, piecewise exponential, Weibull, among other. In order to capture
the unobservable characteristics of each competing cause, we propose here to incorporate a ran-
dom effect (frailty term) on the baseline hazard function that acts multiplicatively in promotion
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time. This approach allows that the competitive causes have different frailties, and that the
most frail will fail earlier than the less frail Wienke (2011).
Let a nonnegative unobservable random variable V that denote the frailty term. The hazard
function of the jth competing cause is given by
h(t|vj ,ϕ) = vjh0(t|ϕ),
where vj represents the frailty for the jth cause and h0(·|ϕ) is baseline hazard function. The
conditional survival function is easily obtained and it is given by
S(t|vj ,ϕ) = S0(t|ϕ)vj ,
where S0(·|ϕ) denotes the baseline survival function.
In this paper, we consider that the random variable V follows the family of power variance
function (PVF) distributions with parameters µ, ψ and γ, suggested by Tweedie (1984) and
derived independently by Hougaard (1986). For more PVF distribution details (see Wienke,
2011). We consider that E(V |µ, ψ, γ) = µ = 1 and Var(V |µ, ψ, γ) = µ2/ψ = σ2, where σ2 is
interpreted as a measure of unobserved heterogeneity. With this restriction, the results PVF
parameters are γ and σ2.
In order to eliminate the unobserved quantities, the random effect can be integrated out.
Thus, marginal survival function is given by
S(t|ϕ∗) = EV [S(t|vj ,ϕ)] =
∫ ∞
0
e−H0(t|,ϕ)vjfv(vj |γ, σ2)dvj = Lv[H0(t|ϕ)],
where ϕ∗ = (ϕ, γ, σ2)>, fv(·|γ, σ2) is the density function of V conditional to γ and σ2, H0(·|ϕ)
is cumulative baseline hazard function and Lv[·] denotes the Laplace transform of frailty distri-
bution.
The unconditional survival and density functions in the PVF frailty model is expressed by
S(t|ϕ∗) = exp
{
1− γ
γσ2
[
1−
(
1 +
σ2H0(t|ϕ)
1− γ
)γ]}
(4)
and
f(t|ϕ∗) = h0(t|ϕ)
(
1 +
σ2H0(t|ϕ)
1− γ
)γ−1
exp
{
1− γ
γσ2
[
1−
(
1 +
σ2H0(t|ϕ)
1− γ
)γ]}
. (5)
Besides providing an algebraic treatment of the closed-form for the marginal survival, the
5
PVF family is a flexible model in the sense to include many other frailty models as special cases.
For instance, the gamma frailty model is obtained if γ = 0 and in the case of γ = 0.5, the inverse
Gaussian distribution is derived. The positive stable is a special case of the PVF distribution,
however to show this fact, some asymptotic considerations are necessary. We refer the interested
readers to Wienke (2011).
This way, as an alternative to the usual cure rate models (3), we propose a new model that
incorporates a frailty term for each competing cause and consider that, conditional on N = n and
on ϕ∗, the latent times follow a survival function as in (4). As the number of competing causes
follows a negative binomial distribution, the population survival function with PVF frailty is
given by
Spop(t|ϑ) =
{
1 + ηθ
(
1− exp
{
1− γ
γσ2
[
1−
(
1 +
σ2H0(t|ϕ)
1− γ
)γ]})}−1/η
, (6)
where ϑ = (ϕ∗,Θ)>.
We assume a Weibull distribution for the cumulative baseline hazard function, given by
H0(t|ϕ) = eαtλ, where α ∈ R, λ > 0 and ϕ = (α, λ)>.
Henceforward, we will refer to the model of which the survival function is as shown in (6),
by PVF frailty cure rate model or simply PVFCR model. Note that usual cure rate model (CR)
(3) is obtained as σ2 → 0.
3 Bayesian inference
Let us consider the situation when the time to event is not completely observed and it
is subject to right censoring. For a given sample of size m, the observed time for ith unit is
Wi = min{Ti, Ci}, with Ti = min{Zi0, Zi1, . . . , ZiNi} and Ci the censoring time, for i = 1, . . . ,m.
Let δi = I(Ti ≤ Ci), that is, δi = 1 if Wi = Ti and δi = 0 otherwise.
We include covariate through the expected number of competing causes by E(Ni|Θ) = θi =
exp{x>i β}, i = 1, . . . ,m, where β is a k × 1 vector of regression coefficients. The observed data
are represented by D = (m,w, δ,X), w = (w1, . . . , wm)
>, δ = (δ1, . . . , δm)> and X is an m× k
matrix containing the covariates.
The likelihood function of parameters ϑ = (ϕ∗,Θ)> = (α, λ, γ, σ2, η,β)> under non-informative
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censoring can be written as
L(ϑ|D) ∝
m∏
i=1
{fpop(wi|ϑ)}δi{Spop(wi|ϑ)}1−δi
∝
m∏
i=1
{
exp(x>i β)f(wi|ϕ∗)
}δi{
1 + η exp(x>i β)[1− S(wi|ϕ∗)]
}− 1
η
−δi
,
where S(wi|ϕ∗) and f(wi|ϕ∗) are given in (4) and (5), respectively.
The posterior distribution of ϑ comes out to be
pi(ϑ|D) ∝ pi(ϑ)λr exp
{
m∑
i=1
δix
>
i β + r
(
α+
1− γ
γσ2
)} m∏
i=1
{
wλ−1i
(
1 +
σ2eαwλi
1− γ
)γ−1}δi
×
m∏
i=1
{
1 + η exp(x>i β)
[
1− exp
{
1− γ
γσ2
[
1−
(
1 +
σ2eαwλi
1− γ
)γ]}]}−1/η−δi
×
m∏
i=1
exp
{
−
(
1− γ
γσ2
)(
1 +
σ2eαwλi
1− γ
)γ}δi
, (7)
where r =
∑m
i=1 δi and pi(ϑ) is prior distribution of ϑ.
We consider independent prior distributions defining them as β ∼ Normalk+1(0, 100I), α ∼
Normal(0, 100), γ ∼ Uniform(0, 1) and η, λ and σ2 follow gamma distribution with mean 1 for
all and variances 1, 100 and 1, respectively.
3.1 Estimation procedure
The posterior density of ϑ in (7) is analytically intractable because the integration of the joint
density is not easy to perform. An alternative is to rely on Markov chain Monte Carlo (MCMC)
simulations. Here we consider Adaptive Metropolis Hasting algorithm with a multivariate dis-
tribution as proposal distribution Haario et al. (2005) implemented in the statistical package
LaplacesDemon Hall (2012), which provides a friendly environment for Bayesian inference within
the R program R Core Team (2016).
As a result, a sample of size np from the joint posterior distribution of ϑ is obtained
(eliminating burn-in and jump samples). The sample from the posterior can be expressed as
(ϑ1,ϑ2, . . . ,ϑnp). The estimator of ϑ considered is given by
ϑ̂ =
1
np
np∑
k=1
ϑk, (8)
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and an estimator of the cure rate is
p̂0 =
1
np
np∑
k=1
(1 + ηkθk)
−1/ηk . (9)
Consider the functions Yk(t) = Spop(t|ϑk) where Spop(t|ϑk) is presented in (6), conditional
to ϑk. The proposed estimator of the improper survival function is
̂Spop(t|ϑ) = 1
np
np∑
k=1
Yk(t), for each t > 0. (10)
3.2 Conditional predictive ordinate (CPO)
A criterion for model selection that can be considered is based on the conditional predictive
ordinates (CPO).
For an observed time to event (δ = 1), we define g(ti|ϑ) = fpop(ti|ϑ) and, for a censored
time, g(ti|ϑ) = Spop(ti|ϑ). For the ith observation, CPOi can be expressed as
CPOi =
∫
g(ti|ϑ)pi(ϑ|D−i)dϑ
=
{∫
pi(ϑ|D)
g(ti|ϑ) dϑ
}−1
.
The CPOi can be interpreted as the height of the marginal density of the time to event
at ti. Thus, large values of CPOi imply a better fit of the model. For the proposed model, a
closed form of the CPOi is not available. However, a Monte Carlo estimate of CPOi can be
obtained by using a single MCMC sample from the posterior distribution pi(ϑ|D). A Monte
Carlo approximation of CPOi is given by:
ĈPOi =
{
1
np
np∑
k=1
1
g(ti|ϑk)
}−1
.
A summary statistic of the CPOi’s is the CPO =
∑m
i=1 log(ĈPOi). The larger the value of
CPO is, the better the fit of the model is Rodrigues et al. (2012).
4 Simulation study
For data generation in this simulation study, we consider the model in (6) with the Weibull
distribution for the cumulative baseline hazard function with α = 0 and λ = 1 (exponential
distribution with rate eα) and one binary covariate X values drawn from a Bernoulli distri-
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bution with parameter 0.5. We take for PVF frailty distribution γ ∈ {0.1, 0.5, 0.9} and
σ2 ∈ {0.5, 1, 1.5, 2}. The failure times data were simulated with η = 0.5, θl = exp(β0 + lβ1),
l = 0, 1, where β0 = −0.5 and β1 = 0.7. In this way, p0l = (1 + ηθl)−1/η, so that the cure rates
for the two levels of X are p00 = 0.59 and p01 = 0.39. The censoring times were sampled from
the exponential distribution with τ parameter (rate), where τ was set in order to control the
proportion of censored observations. An algorithm to generate observed times and censoring
indicators is:
1. Draw Xi ∼ Bernoulli(0.5) and ui ∼ Uniform(0, 1).
2. Let Xi = l. If ui < p0l, ti =∞, otherwise,
ti =
(1− γ)
σ2eα
({
1− γσ
2
1− γ log
[
1−
(
u−η − 1
η exp(β0 + β1xi)
)]}1/γ
− 1
)
.
3. Draw
ci ∼ Exponential (τ) , τ = e
η(pcl − p0l)
1− (pcl − p0l) , where pcl = p0l + 0.01.
4. Let wi = min{ti, ci}.
5. If ti < ci, set δi = 1, otherwise, δi = 0, for i = 1, . . . ,m.
We consider four sample sizes, m = 100, 300, 500 and 1000. For each scenario (each combi-
nation of parameters values and sample size), we simulated B = 1000 random samples.
As said previously, the Bayesian estimation procedures were performed using Adaptive
Metropolis-Hastings algorithm such that the estimation of covariance matrix is update every
100 iterations. For PVFCR and CR models, we generated 40000 and 30000 values for each pa-
rameter, respectively, disregarding the first 10000 iterations to eliminate the effect of the initial
values and spacing of size 30 and 20, respectively, to avoid correlation problems, obtaining a
sample of size np = 1000. The chains convergence was monitored for all simulation scenario,
where good convergence results were obtained.
For each random sample, the estimates of ϑ and cure rate are obtained by (8) and (9). We
computed the average of B estimates of ϑ (AE) and the root of the mean squared error (RMSE)
of the estimators obtained from PVFCR and CR models. The results are all summarized in
Tables 1-3.
The results show that for both models, the average estimates of p00 and p01 were not affected
by the increase of γ and σ2 values. Even for small sample sizes, the average estimates were close
9
to fixed values. For the PVFCR model, we observe that the RMSEs appear reasonably close to
zero as sample size increases, except for σ2 parameter, which needs large sample size to close
to zero. For a fixed sample size, the RMSE of σ2 estimation increases as σ2 also increases,
regardless of γ values.
We can note that the η estimation obtained from CR model provides, in average, large
RMSE, even when sample size is large, and this fact is more evident when γ = 0.1 and 0.5.
However, if γ = 0.9 the RMSE decreases as sample size increases.
It is worth mention that the inclusion of frailty term in the cure rate model (PVFCR) pro-
vides, in general, lower RMSE when compared to RMSE obtained by CR model. This behavior
is clearly observed when γ = 0.1 and 0.5. Some exceptions occur, however for large sample
size (m = 1000) the PVFCR model fit provides, in average, lower RMSE for the estimators,
regardless of degree unobserved heterogeneity.
For models comparison, we considered the difference between the CPO values obtained under
the fitted PVFCR and CR models. For a fixed scenario, we evaluate the mean difference and
standard deviation of the B = 1000 CPO’s difference. This way, a positive CPO mean difference
means that, in average, the CPO of the fitted PVFCR model is larger than CPO obtained from
the fitted CR model, which shows advantage of the proposed model.
In Figure 1, we present the CPO mean difference for all considered scenarios. For a fixed
sample size and when γ = 0.1 or 0.5, CPO mean difference increases as σ2 increases, which
stabilizes in σ2 = 1.5 and 2. Besides, as sample size increases, CPO mean difference also
increases, which indicates best fits of PVFCR model. By the other hand, when γ = 0.9 the
CPO mean difference is always negative, which favors the CR model, even with large unobserved
heterogeneity.
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Table 1: Root of the mean squared error (RMSE) and average of estimates (AE) of the estimators
for simulated data from PVFCR model when p00 = 0.59, p01 = 0.39, β0 = −0.5, β1 = 0.7, α = 0,
λ = 1, η = 0.5 and γ = 0.1.
m 100 300 500 1000
σ2 Parameters Model RMSE AE RMSE AE RMSE AE RMSE AE
p00 PVFCR 0.073 0.586 0.040 0.585 0.032 0.588 0.023 0.589
CR 0.076 0.578 0.044 0.576 0.036 0.577 0.027 0.578
p01 PVFCR 0.068 0.400 0.039 0.396 0.031 0.393 0.023 0.391
CR 0.066 0.396 0.039 0.395 0.031 0.393 0.024 0.394
β0 PVFCR 0.561 -0.178 0.365 -0.269 0.282 -0.341 0.190 -0.409
CR 0.763 -0.013 0.609 -0.058 0.532 -0.102 0.448 -0.142
β1 PVFCR 0.493 0.877 0.261 0.811 0.203 0.788 0.147 0.753
CR 0.515 0.904 0.302 0.869 0.258 0.867 0.215 0.858
0.5 η PVFCR 1.075 1.428 0.871 1.175 0.696 0.988 0.503 0.795
CR 1.404 1.714 1.394 1.647 1.288 1.564 1.163 1.495
α PVFCR 0.450 -0.247 0.305 -0.160 0.245 -0.091 0.190 -0.026
CR 0.784 -0.687 0.700 -0.640 0.656 -0.611 0.617 -0.589
λ PVFCR 0.203 1.103 0.126 1.057 0.100 1.046 0.080 1.039
CR 0.152 0.952 0.128 0.913 0.126 0.901 0.125 0.890
γ PVFCR 0.352 0.439 0.320 0.398 0.292 0.368 0.237 0.312
σ2 PVFCR 0.642 1.065 0.532 0.965 0.491 0.917 0.413 0.821
p00 PVFCR 0.072 0.586 0.043 0.586 0.032 0.587 0.022 0.589
CR 0.080 0.571 0.052 0.570 0.042 0.569 0.033 0.568
p01 PVFCR 0.070 0.400 0.039 0.393 0.031 0.395 0.022 0.391
CR 0.068 0.394 0.039 0.395 0.033 0.400 0.027 0.401
β0 PVFCR 0.578 -0.144 0.396 -0.251 0.316 -0.310 0.217 -0.384
CR 1.025 0.180 0.920 0.186 0.879 0.198 0.799 0.187
β1 PVFCR 0.498 0.890 0.286 0.840 0.211 0.797 0.153 0.772
CR 0.537 0.940 0.364 0.941 0.310 0.929 0.290 0.950
1 η PVFCR 1.119 1.498 0.933 1.229 0.794 1.072 0.579 0.870
CR 1.730 2.021 1.938 2.163 2.008 2.244 1.968 2.285
α PVFCR 0.602 -0.409 0.420 -0.240 0.335 -0.153 0.240 -0.074
CR 1.211 -1.073 1.134 -1.048 1.112 -1.052 1.089 -1.052
λ PVFCR 0.182 1.046 0.122 1.035 0.104 1.034 0.075 1.032
CR 0.192 0.858 0.188 0.838 0.190 0.832 0.180 0.832
γ PVFCR 0.298 0.377 0.224 0.293 0.182 0.252 0.138 0.213
σ2 PVFCR 0.547 1.324 0.533 1.329 0.529 1.336 0.443 1.287
p00 PVFCR 0.077 0.581 0.044 0.586 0.032 0.586 0.024 0.587
CR 0.091 0.561 0.056 0.565 0.046 0.563 0.041 0.561
p01 PVFCR 0.069 0.401 0.042 0.397 0.035 0.396 0.024 0.391
CR 0.068 0.393 0.043 0.404 0.040 0.409 0.035 0.412
β0 PVFCR 0.713 -0.067 0.422 -0.236 0.345 -0.286 0.234 -0.369
CR 1.416 0.422 1.243 0.452 1.283 0.536 1.203 0.549
β1 PVFCR 0.508 0.888 0.277 0.819 0.211 0.798 0.158 0.771
CR 0.571 0.953 0.387 0.954 0.359 0.980 0.346 1.003
1.5 η PVFCR 1.238 1.596 0.947 1.256 0.850 1.127 0.610 0.901
CR 2.010 2.273 2.544 2.704 2.811 2.969 2.809 3.089
α PVFCR 0.845 -0.594 0.480 -0.291 0.397 -0.224 0.279 -0.127
CR 1.683 -1.431 1.485 -1.379 1.546 -1.450 1.517 -1.463
λ PVFCR 0.176 0.993 0.123 1.015 0.103 1.020 0.073 1.017
CR 0.230 0.807 0.217 0.810 0.205 0.821 0.194 0.822
γ PVFCR 0.277 0.357 0.182 0.251 0.142 0.215 0.099 0.176
σ2 PVFCR 0.521 1.484 0.611 1.699 0.590 1.754 0.480 1.724
p00 PVFCR 0.082 0.586 0.044 0.585 0.034 0.589 0.025 0.587
CR 0.102 0.560 0.061 0.562 0.049 0.564 0.044 0.559
p01 PVFCR 0.078 0.408 0.043 0.400 0.035 0.398 0.024 0.392
CR 0.079 0.396 0.045 0.410 0.045 0.418 0.043 0.423
β0 PVFCR 1.292 -0.052 0.433 -0.216 0.310 -0.311 0.244 -0.361
CR 2.522 0.621 1.758 0.725 1.544 0.749 1.620 0.902
β1 PVFCR 0.580 0.879 0.280 0.820 0.215 0.795 0.159 0.773
CR 0.760 0.962 0.418 0.984 0.392 1.009 0.393 1.051
2 η PVFCR 1.620 1.610 1.005 1.310 0.777 1.090 0.631 0.919
CR 3.092 2.435 3.134 3.191 3.314 3.462 3.658 3.872
α PVFCR 1.231 -0.713 0.567 -0.397 0.425 -0.251 0.333 -0.171
CR 2.424 -1.705 1.972 -1.711 1.840 -1.723 1.924 -1.839
λ PVFCR 0.201 0.938 0.123 0.977 0.103 0.997 0.077 1.003
CR 0.320 0.770 0.234 0.796 0.219 0.808 0.196 0.830
γ PVFCR 0.275 0.357 0.171 0.241 0.120 0.194 0.085 0.162
σ2 PVFCR 0.711 1.551 0.670 1.970 0.642 2.110 0.609 2.192
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Table 2: Root of the mean squared error (RMSE) and average of estimates (AE) of the estimators
for simulated data from PVFCR model when p00 = 0.59, p01 = 0.39, β0 = −0.5, β1 = 0.7, α = 0,
λ = 1, η = 0.5 and γ = 0.5.
m 100 300 500 1000
σ2 Parameters Model RMSE AE RMSE AE RMSE AE RMSE AE
p00 PVFCR 0.071 0.587 0.039 0.588 0.032 0.587 0.022 0.588
CR 0.073 0.580 0.042 0.581 0.035 0.581 0.024 0.581
p01 PVFCR 0.069 0.403 0.038 0.395 0.031 0.392 0.022 0.389
CR 0.067 0.399 0.037 0.394 0.031 0.393 0.022 0.391
β0 PVFCR 0.545 -0.192 0.338 -0.299 0.294 -0.334 0.198 -0.393
CR 0.696 -0.067 0.505 -0.152 0.473 -0.172 0.367 -0.219
β1 PVFCR 0.465 0.857 0.257 0.810 0.203 0.793 0.150 0.765
CR 0.484 0.883 0.291 0.857 0.246 0.852 0.204 0.842
0.5 η PVFCR 1.055 1.394 0.825 1.116 0.727 1.008 0.531 0.835
CR 1.322 1.619 1.197 1.453 1.153 1.409 0.981 1.303
α PVFCR 0.405 -0.210 0.289 -0.155 0.247 -0.133 0.188 -0.092
CR 0.664 -0.572 0.566 -0.509 0.543 -0.496 0.495 -0.467
λ PVFCR 0.205 1.116 0.116 1.053 0.095 1.039 0.065 1.019
CR 0.142 0.991 0.100 0.951 0.094 0.943 0.089 0.930
γ PVFCR 0.085 0.471 0.103 0.481 0.110 0.476 0.112 0.467
σ2 PVFCR 0.545 0.988 0.445 0.891 0.407 0.844 0.381 0.788
p00 PVFCR 0.073 0.588 0.041 0.588 0.033 0.588 0.023 0.587
CR 0.075 0.581 0.044 0.580 0.036 0.579 0.028 0.577
p01 PVFCR 0.072 0.404 0.038 0.396 0.031 0.394 0.021 0.390
CR 0.070 0.401 0.038 0.395 0.031 0.395 0.023 0.394
β0 PVFCR 0.560 -0.182 0.392 -0.262 0.318 -0.307 0.232 -0.367
CR 0.738 -0.032 0.631 -0.053 0.572 -0.074 0.505 -0.091
β1 PVFCR 0.481 0.871 0.288 0.837 0.218 0.810 0.159 0.775
CR 0.507 0.904 0.334 0.898 0.277 0.889 0.236 0.882
1 η PVFCR 1.097 1.444 0.948 1.227 0.805 1.095 0.618 0.905
CR 1.414 1.716 1.472 1.703 1.398 1.663 1.307 1.626
α PVFCR 0.538 -0.375 0.419 -0.310 0.360 -0.267 0.290 -0.192
CR 0.858 -0.769 0.802 -0.746 0.768 -0.725 0.741 -0.713
λ PVFCR 0.168 1.064 0.108 1.015 0.086 1.001 0.069 0.996
CR 0.145 0.935 0.135 0.901 0.131 0.894 0.127 0.888
γ PVFCR 0.094 0.455 0.121 0.444 0.124 0.436 0.127 0.422
σ2 PVFCR 0.293 1.056 0.278 0.990 0.273 0.956 0.325 0.960
p00 PVFCR 0.068 0.585 0.042 0.585 0.033 0.586 0.023 0.586
CR 0.071 0.576 0.045 0.576 0.037 0.576 0.029 0.574
p01 PVFCR 0.068 0.399 0.039 0.395 0.031 0.394 0.022 0.389
CR 0.066 0.396 0.039 0.396 0.032 0.397 0.024 0.395
β0 PVFCR 0.584 -0.135 0.438 -0.220 0.333 -0.289 0.254 -0.344
CR 0.808 0.049 0.729 0.033 0.657 0.009 0.615 0.005
β1 PVFCR 0.505 0.892 0.298 0.845 0.215 0.808 0.163 0.785
CR 0.538 0.928 0.353 0.916 0.288 0.902 0.263 0.914
1.5 η PVFCR 1.167 1.516 1.048 1.309 0.836 1.130 0.673 0.961
CR 1.548 1.850 1.660 1.878 1.590 1.847 1.554 1.856
α PVFCR 0.667 -0.534 0.536 -0.434 0.442 -0.359 0.369 -0.293
CR 1.040 -0.962 0.972 -0.912 0.938 -0.896 0.933 -0.902
λ PVFCR 0.164 1.027 0.108 0.983 0.089 0.973 0.073 0.970
CR 0.164 0.892 0.159 0.872 0.156 0.861 0.154 0.860
γ PVFCR 0.108 0.437 0.124 0.431 0.133 0.416 0.137 0.404
σ2 PVFCR 0.496 1.118 0.538 1.064 0.533 1.080 0.540 1.095
p00 PVFCR 0.072 0.582 0.042 0.585 0.034 0.583 0.024 0.585
CR 0.076 0.574 0.046 0.576 0.040 0.572 0.030 0.572
p01 PVFCR 0.066 0.395 0.038 0.393 0.030 0.392 0.021 0.390
CR 0.065 0.393 0.038 0.394 0.032 0.396 0.024 0.397
β0 PVFCR 0.589 -0.128 0.463 -0.216 0.391 -0.245 0.269 -0.334
CR 0.825 0.062 0.768 0.056 0.756 0.086 0.668 0.059
β1 PVFCR 0.483 0.894 0.289 0.850 0.239 0.823 0.162 0.784
CR 0.516 0.931 0.354 0.929 0.314 0.922 0.273 0.925
2 η PVFCR 1.140 1.502 1.056 1.307 0.961 1.214 0.696 0.979
CR 1.529 1.845 1.727 1.923 1.777 1.996 1.676 1.981
α PVFCR 0.751 -0.632 0.621 -0.530 0.572 -0.491 0.441 -0.370
CR 1.125 -1.053 1.089 -1.027 1.094 -1.042 1.055 -1.024
λ PVFCR 0.154 0.988 0.110 0.957 0.099 0.950 0.083 0.950
CR 0.182 0.864 0.181 0.845 0.174 0.847 0.171 0.842
γ PVFCR 0.105 0.438 0.130 0.419 0.133 0.415 0.132 0.407
σ2 PVFCR 0.920 1.147 0.948 1.112 0.946 1.117 0.890 1.211
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Table 3: Root of the mean squared error (RMSE) and average of estimates (AE) of the estimators
for simulated data from PVFCR model when p00 = 0.59, p01 = 0.39, β0 = −0.5, β1 = 0.7, α = 0,
λ = 1, η = 0.5 and γ = 0.9.
m 100 300 500 1000
σ2 Parameters Model RMSE AE RMSE AE RMSE AE RMSE AE
p00 PVFCR 0.069 0.591 0.041 0.590 0.030 0.591 0.021 0.591
CR 0.070 0.587 0.042 0.586 0.030 0.588 0.021 0.588
p01 PVFCR 0.069 0.405 0.041 0.398 0.032 0.393 0.022 0.390
CR 0.067 0.402 0.041 0.397 0.031 0.393 0.022 0.389
β0 PVFCR 0.478 -0.243 0.305 -0.339 0.229 -0.393 0.157 -0.445
CR 0.552 -0.173 0.384 -0.265 0.302 -0.326 0.214 -0.384
β1 PVFCR 0.469 0.854 0.260 0.791 0.198 0.775 0.133 0.744
CR 0.482 0.873 0.280 0.819 0.219 0.805 0.154 0.776
0.5 η PVFCR 0.968 1.321 0.736 1.027 0.600 0.875 0.416 0.704
CR 1.123 1.456 0.937 1.204 0.795 1.049 0.583 0.876
α PVFCR 0.330 -0.110 0.207 -0.075 0.166 -0.054 0.124 -0.030
CR 0.467 -0.378 0.355 -0.295 0.303 -0.255 0.247 -0.216
λ PVFCR 0.235 1.162 0.128 1.084 0.097 1.058 0.062 1.031
CR 0.156 1.062 0.091 1.017 0.073 1.000 0.054 0.982
γ PVFCR 0.394 0.511 0.335 0.572 0.307 0.602 0.278 0.634
σ2 PVFCR 0.437 0.901 0.345 0.813 0.326 0.785 0.325 0.764
p00 PVFCR 0.072 0.593 0.039 0.591 0.030 0.589 0.022 0.589
CR 0.072 0.589 0.039 0.587 0.031 0.586 0.023 0.587
p01 PVFCR 0.066 0.400 0.041 0.396 0.031 0.393 0.021 0.390
CR 0.065 0.397 0.040 0.395 0.031 0.392 0.021 0.389
β0 PVFCR 0.490 -0.253 0.296 -0.350 0.229 -0.382 0.164 -0.439
CR 0.570 -0.180 0.376 -0.279 0.298 -0.317 0.220 -0.378
β1 PVFCR 0.478 0.885 0.262 0.799 0.196 0.768 0.134 0.739
CR 0.495 0.906 0.281 0.826 0.215 0.798 0.154 0.770
1 η PVFCR 0.979 1.322 0.729 1.007 0.587 0.883 0.422 0.702
CR 1.144 1.460 0.922 1.175 0.770 1.052 0.589 0.874
α PVFCR 0.356 -0.157 0.228 -0.124 0.189 -0.111 0.144 -0.081
CR 0.512 -0.425 0.390 -0.336 0.345 -0.307 0.291 -0.263
λ PVFCR 0.226 1.152 0.117 1.069 0.085 1.045 0.055 1.016
CR 0.150 1.053 0.087 1.004 0.069 0.989 0.059 0.969
γ PVFCR 0.393 0.512 0.331 0.576 0.303 0.605 0.274 0.637
σ2 PVFCR 0.193 0.908 0.233 0.813 0.260 0.790 0.293 0.772
p00 PVFCR 0.069 0.593 0.040 0.590 0.032 0.590 0.021 0.589
CR 0.069 0.589 0.041 0.587 0.032 0.587 0.022 0.586
p01 PVFCR 0.067 0.400 0.039 0.396 0.030 0.394 0.020 0.389
CR 0.066 0.397 0.039 0.395 0.030 0.393 0.020 0.389
β0 PVFCR 0.470 -0.256 0.302 -0.344 0.241 -0.385 0.164 -0.434
CR 0.546 -0.183 0.380 -0.272 0.318 -0.313 0.222 -0.373
β1 PVFCR 0.492 0.890 0.262 0.798 0.197 0.769 0.138 0.742
CR 0.510 0.910 0.280 0.825 0.218 0.801 0.159 0.773
1.5 η PVFCR 0.991 1.321 0.720 1.014 0.607 0.884 0.441 0.716
CR 1.148 1.460 0.910 1.185 0.812 1.069 0.606 0.888
α PVFCR 0.358 -0.190 0.255 -0.168 0.215 -0.146 0.175 -0.122
CR 0.528 -0.453 0.426 -0.379 0.387 -0.347 0.330 -0.302
λ PVFCR 0.212 1.137 0.108 1.063 0.082 1.038 0.055 1.010
CR 0.144 1.040 0.081 0.999 0.072 0.982 0.063 0.964
γ PVFCR 0.392 0.512 0.330 0.576 0.306 0.603 0.265 0.646
σ2 PVFCR 0.615 0.908 0.696 0.819 0.719 0.797 0.742 0.779
p00 PVFCR 0.069 0.596 0.040 0.590 0.030 0.590 0.021 0.589
CR 0.069 0.592 0.041 0.587 0.030 0.587 0.022 0.586
p01 PVFCR 0.069 0.401 0.039 0.398 0.032 0.394 0.022 0.391
CR 0.068 0.398 0.038 0.396 0.032 0.393 0.022 0.391
β0 PVFCR 0.477 -0.264 0.296 -0.347 0.225 -0.390 0.167 -0.432
CR 0.554 -0.195 0.373 -0.276 0.296 -0.323 0.226 -0.370
β1 PVFCR 0.485 0.894 0.253 0.788 0.192 0.765 0.136 0.737
CR 0.499 0.914 0.270 0.814 0.211 0.793 0.155 0.768
2 η PVFCR 0.977 1.327 0.718 1.009 0.578 0.869 0.434 0.721
CR 1.131 1.458 0.911 1.177 0.768 1.038 0.606 0.894
α PVFCR 0.377 -0.222 0.268 -0.195 0.224 -0.166 0.191 -0.149
CR 0.557 -0.479 0.443 -0.399 0.391 -0.355 0.350 -0.326
λ PVFCR 0.203 1.131 0.101 1.050 0.077 1.028 0.053 1.004
CR 0.138 1.035 0.082 0.988 0.073 0.975 0.065 0.960
γ PVFCR 0.393 0.511 0.327 0.579 0.299 0.610 0.265 0.647
σ2 PVFCR 1.107 0.905 1.201 0.807 1.221 0.788 1.231 0.782
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(c) γ = 0.9
Figure 1: Mean difference (symbol) between the CPO values obtained under the fitted PVFCR
and CR models and ± standard deviation of the difference (bar) when the data are generated
from PVFCR model (a) for γ = 0.1, (b) for γ = 0.5 and (c) for γ = 0.9.
5 Application
In this section, the proposed model and CR model are fitted to a real data set. The data
are part of a study about cutaneous melanoma for the evaluating of postoperative treatment
performance with a high dose of interferon alfa-2b drug in order to prevent recurrence. Patients
were included in the study from 1991 to 1995 and follow-up was conducted until 1998. The
data were collected by Ibrahim et al. (2001) where survival time is defined as the time until the
patient’s death. The sample size is m = 417 patients and the percentage of censored observations
is 56%. The explanatory variables measured at baseline are: treatment (control or interferon),
age (in years), sex, performance status (patient’s functional capacity scale) and nodule category
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(categorization of number of lymph nodes: category 1 if 0 lymph node, category 2 if 1 lymph
node, category 3 if 2 or 3 lymph nodes and category 4 if lymph nodes ≥ 4).
For fitted PVFCR and CR models, we considered np = 1000, where the first 10000 iterations
were eliminated as burn-in samples and considered jump of size 100. The estimates of ϑ and cure
rate are obtained by (8) and (9), respectively, and the estimator of improper survival function
is given by (10).
Except nodule category, all regression coefficients are non-significant for both fitted model.
Then, in Table 4 is presented the summaries of parameters estimates of final model (considering
only dummies variables of nodule category as explanatory variable, where the lowest category
is baseline). We can note that the standard deviation of all the parameters are lower for the
proposed model, as well as the HPD intervals have lower amplitudes. Furthermore, PVFCR
model showed a slightly higher CPO value (CPO = −516.4 for PVFCR model versus CPO =
−516.6 for CR model). Although the inference is the same for both models: only the explanatory
variable nodule category is significant, the models provides similar fit for survival curves (Figure
3) and category 1 is statistically different from categories 3 and 4 that have the lowest cure
rate; HPD intervals of cure rates have lower amplitudes for PVFCR model, as we can observed
in Figure 2. Besides we emphasize the importance of the proposed model in capture and in
quantifying the degree of unobservable heterogeneity.
Table 4: Parameters posterior mean, standard deviation (SD) and Highest Probability Density
interval (HPD) of fitted PVFCR and CR models.
PVFCR model CR model
Parameter Mean SD
HPD 95%
Mean SD
HPD 95%
Lower Upper Lower Upper
λ 2.355 0.267 1.852 2.863 2.307 0.296 1.716 2.822
α -3.147 0.856 -4.859 -1.802 -3.889 2.216 -8.070 -1.705
η 2.919 1.330 0.596 5.651 3.670 1.461 0.939 6.414
β0 0.233 0.743 -0.928 1.571 0.886 2.145 -0.901 4.816
βD2 0.674 0.396 -0.026 1.501 0.809 0.431 -0.039 1.599
βD3 1.313 0.522 0.382 2.368 1.503 0.576 0.496 2.556
βD4 2.108 0.519 1.156 3.144 2.295 0.532 1.305 3.322
γ 0.413 0.264 0.002 0.904 - - - -
σ2 1.270 1.067 0.007 3.378 - - - -
1βDl is the parameter associated to lth dummy variable that is indicates lth nodule category,
for l = 2, 3, 4 (category 1 is baseline).
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Figure 2: Cure rate estimates (symbol) and HPD interval (bar) according to fitted PVFCR and
CR models.
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Figure 3: Survival estimates curves by PVFCR model (solid line) and CR model (dotted)
stratified by nodule category (1-4 from top to bottom).
6 Final remarks
In this paper, we look at the cure rate model formulated by Cancho et al. (2011) in a
different way, that is, we considered a random unobservable effect in promotion time of each
competing cause, which allows to quantify the unobserved heterogeneity. The PVF frailty model
was considered for the latent variables and it includes many other frailty models as special cases,
being of great interesting. A simulation study was conducted to illustrate the good performance
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of the Bayesian estimators of the proposed model, where the RMSE appears reasonably close
to zero as sample size increases. The results indicated lower RMSE for the estimators of the
proposed model parameters, mainly in presence of large unobservable heterogeneity. As in
practice situation the choice of the model is often based on a selection criterion, we evaluated
the performance of model in terms of CPO criterion (higher values are desirable) when it is
compared to usual cure rate model Cancho et al. (2011). We observed that, in average, the
CPO of fitted proposed model is largest, exception when γ close to one. The practical relevance
and applicability of the proposed model is demonstrated in a real data set, which our model
yields a slight better fit than the usual cure rate model. We hope this generalization may attract
wider applications in survival analysis. The computational codes can be requested for the first
author.
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